Middle East And Africa Prophylaxis Of Organ Rejection Market, By Cause (Epidemiologic Exposure, Antibacterial Prophylaxis, Prophylaxis Against Other Pathogens And Others), Treatment (Outpatient Immunosuppressant, Inpatient Immunosuppressant And Others), Route Of Administration (Oral, Intravenous), Organ (Kidney, Liver, Heart, Lung, Others), Patient Type (Pediatric, Adults), End User (Hospitals, Clinic Home Healthcare And Others), Distribution Channel (Direct Tender, Pharmacy Stores And Others), Country (Saudi Arabia, South Africa, Israel, Kuwait, UAE And Rest Of Middle East & Africa), Market Trends And Forecast To 2029.
Market Analysis and Insights : Middle East and Africa Prophylaxis of Organ Rejection Market
Middle East and Africa prophylaxis of organ rejection market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 2.0% in the forecast period of 2022 to 2029 and is expected to reach USD 69.23 million by 2029 from USD 59.81 million in 2021. The rising prevalence of organ transplantation and increased use of immunosuppressant are likely to be the major drivers which propel the demand of the market in the forecast period.
The term prophylaxis means treatment given or action taken to prevent disease. The prophylaxis of organ rejection, refers to the prevention of organ rejection by use of medicines. The patients who undergo transplantation, must be maintained on an immunosuppression regimen for rejection prophylaxis to help ensure graft survival. The transplant rejection is a process, in which a transplant recipient’s immunity the current rejection prophylaxis implements use of calcineurin inhibitors, mTOR inhibitors, antimetabolite agents, and corticosteroids. The treatment agents improve the short term consequences of the organ transplantation, but certain improvements. The recipient patients, who have undergone solid organ transplantation, should take anti-rejection medicines. This is because the immunity system would destroy the transplanted organ.
The driving factors responsible for the growth of the Middle East and Africa prophylaxis of organ rejection market are the increased prevalence of organ transplantation, rise in surgical procedures, rise in recipient population and product launches. However, the factors that are expected to restrain the market are the rise in the cost of the transplantation procedure, lack of awareness about organ transplantation and the risks included while the patient receives the transplanted organ.
- On the other hand, strategic initiatives by market players, rise in research and developments and use of immunosuppressant may act as an opportunity for the growth of the Middle East and Africa prophylaxis of organ rejection market. The need for skilled expertise and the regulatory approval may create challenges for the Middle East and Africa prophylaxis of organ rejection market. There are recent developments related to the Middle East and Africa prophylaxis of organ rejection market. The Middle East and Africa prophylaxis of organ rejection market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Middle East and Africa Prophylaxis of Organ Rejection Market Scope and Market Size
Middle East and Africa prophylaxis of organ rejection market is categorized into seven segments: cause, treatment, route of administration, organ, patient type, end user and distribution channel.
- On the basis of cause, the Middle East and Africa prophylaxis of organ rejection market is segmented into epidemiologic exposure, antibacterial prophylaxis, prophylaxis against other pathogens and others. In 2022, the epidemiologic exposure segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market due to availability of direct information and presence of pathogens related to prophylaxis of organ rejection in U.A.E
- On the basis of treatment, the Middle East and Africa prophylaxis of organ rejection market is segmented into outpatient immunosuppressant, inpatient immunosuppressant and others. In 2022, the outpatient immunosuppressant segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market, since it can achieve the sustained and specific immune response against damaged cells and availability of cyclosporine.
- On the basis of route of administration, the Middle East and Africa prophylaxis of organ rejection market is segmented into oral and intravenous. In 2022, the oral segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection due to increased availability and intake of oral tablets and capsules.
- On the basis of organ, the Middle East and Africa prophylaxis of organ rejection market is segmented into kidney, liver, heart, lung and others. In 2022, the kidney segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection due to increased incidence of kidney failure and presence of reimbursement policies such as Medicare, for the recipient’s insurance.
- On the basis of patient type, the Middle East and Africa prophylaxis of organ rejection market is segmented into pediatric and adults. In 2022, the adults segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market, due to increased prevalence of chronic diseases and genetic conditions of the adult patients, weak immune system in adults and waiting list of adult recipients more than the waiting list of children and women.
- On the basis of end user, the Middle East and Africa prophylaxis of organ rejection market is segmented into hospitals, clinics, home healthcare and others. In 2022, the hospitals segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market due to rise in medical care and collaboration with other hospitals in Middle East and Africa for delivery of the donor organs to the recipient patients are predicted to dominate the market.
- On the basis of distribution channel, the Middle East and Africa prophylaxis of organ rejection market is segmented into direct tenders, pharmacy stores and others. In 2022, the direct tenders segment is expected to dominate the Middle East and Africa prophylaxis of organ rejection market due to surge in demand of outpatient immunosuppressant by pharmaceutical companies and guaranteed payment, are predicted to dominate the market
Middle East and Africa Prophylaxis of Organ Rejection Market Country Level Analysis
Middle East and Africa prophylaxis of organ rejection market is categorized into seven segments: cause, treatment, route of administration, organ, patient type, end user and distribution channel.
The countries covered in the Middle-East and Africa Prophylaxis of Organ Rejection market report are the South Africa, Saudi Arabia, UAE, Egypt, Israel & Rest of Middle East and Africa.
Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2029 as Middle East and Africa counties are major developing countries and focus on increasing R&D activities in pharma and biotech sector and increase outsourcing services. South Africa is expected to dominate in the market in the Middle East and Africa market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Growth Potential for the Prophylaxis of Organ Rejection in Emerging Economies and the Strategic Initiatives by Market Players are Creating New Opportunities in the Middle East and Africa Cleanroom Prophylaxis of Organ Rejection Market.
Middle East and Africa prophylaxis of organ rejection also provides you with detailed market analysis for every country growth in particular industry with the cleanroom particle counters sales, impact of advancement in the organ rejection in regulatory scenarios with their support for the Middle East and Africa cleanroom prophylaxis of organ rejection market. The data is available for historic period 2020 to 2021.
Competitive Landscape and Middle East and Africa Prophylaxis of Organ Rejection Market: Share Analysis
Middle East and Africa prophylaxis of organ rejection competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to cleanroom particle counters market.
The major companies providing the Middle East and Africa Prophylaxis of Organ Rejection are Panacea Biotec, WOCKHARDT, Accord-UK Ltd, Veloxis Pharmaceuticals, Inc, Astellas Pharma Inc, Novartis AG, Bristol-Myers Squibb Company, Dr Reddy’s Laboratories, Ltd, Viatris Inc, Glenmark, Biocon, Pfizer Inc, Mayne Pharma Group Limited, Hikma Pharmaceuticals PLC, AbbVie Inc., Apotex Inc, Zydus Pharmaceuticals, Inc, and CSL Behring among others.
The strategic initiatives by market players along with new technological advancements for the prophylaxis of organ rejection bridges the gap for the organ transplant.
For instance,
- In November 2020, Concord Biotech and Lupin had received the U.S. FDA approval for generic immunosuppressant capsules. The approval received would increase the sale of the immunosuppressant capsules used in organ rejection.
Collaboration, joint ventures and other strategies by the market player is enhancing the company market in the Middle East and Africa prophylaxis of organ rejection which also provides the benefit for organisation to improve their offering for Treatment Products.
SKU-